A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Gene Expression Profiling
  • Genes, Neoplasm

abstract

  • A genomic predictor combining ER status, predicted chemoresistance, predicted chemosensitivity, and predicted endocrine sensitivity identified patients with high probability of survival following taxane and anthracycline chemotherapy.

publication date

  • May 11, 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5638042

Digital Object Identifier (DOI)

  • 10.1001/jama.2011.593

PubMed ID

  • 21558518

Additional Document Info

start page

  • 1873

end page

  • 81

volume

  • 305

number

  • 18